Medicare must study expensive drug

The cost of caring for America’s nearly 6 million Alzheimer’s disease patients is already $600 billion a year, factoring in the cost of uncompensated caregiving. Now, the Food and Drug Administration has approved a drug treatment that may or may not work but is set to cost $56,000 a year for the average patient — a charge that in most instances will fall to Medicare.